EU fines six for pay-for-delay

Share this article:

The European Union is fining drugmakers over efforts to keep generics of the blood-pressure drug perindopril off the market.

Bloomberg reports that the EU has fined six drugmakers, including brand owner Les Laboratories Servier ($451 million) and generic maker Teva ($21 million), over the pay-for-delay strategy which extended the brand's hold on the marketplace.

Bloomberg says the EU's accusations against Servier included making agreements with generics makers to keep generics out of pharmacies and acquiring competing technologies.

Krka Group, Mylan Laboratories, Unichem Laboratories and Lupin Ltd., were also fined.

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.